Prevalence Of Renal Dysfunction In Patients With Chronic Liver Disease Admitted To Sohag University Hospital

To find out the prevalence of renal dysfunction in chronic liver disease patients who admitted to sohag university hospital

Study Overview

• Status: Not yet recruiting
• Conditions: Renal Dysfunction
• Intervention / Treatment: Other: No intervention (observational study)

Detailed Description

The interrelationship between liver disease and renal dysfunction was recognized as early as the era of Hippocrates and this has been the object of a considerable amount of research since then. Kidney dysfunction in liver disease can be due to different etiologies and can have diverse manifestations. Most of the abnormalities of kidney function in cirrhosis are of functional origin- namely, sodium retention, impaired free water excretion, and renal vasoconstriction with a decrease in renal perfusion and glomerular filtration rate.

Renal dysfunction in chronic liver disease usually follows a progressive course - the final phase being Hepatorenal syndrome (HRS).

There is no explanation that fully defines the complex relationship between the diseased liver and disturbances in kidney function, though substantial progress is being made in recent years regarding research in this aspect. One of the most difficult issues in the clinical evaluation of patients with cirrhosis is the accurate assessment of renal function. Standard measures of renal function like blood urea nitrogen and serum creatinine are likely to give erroneous impressions and hence alternative methods to determine renal reserve must be used.

Kidney function is evaluated by assessing the glomerular filtration rate (GFR) For many years now, the assessment of GFR has relied on the measurement of the concentration of serum creatinine, which is associated with many problems. Creatinine is a product of the metabolism of creatine, produced in the liver from three amino acids, methionine, arginine, and glycine, and stored in muscle to be used as a source of energy once phosphorylated. Creatinine does not appear in the plasma at a constant rate; it is secreted in the tubule and can undergo extrarenal elimination, thought to involve creatinase in the gut. Serum creatinine concentration displays an exponential relationship with GFR, rendering it specific, but not a sensitive measure of GFR. The creatinine pool is affected by gender, age, ethnicity, nutritional state, protein intake, and importantly liver disease. 1 In chronic liver disease, the reduction in the serum creatinine pool is due to a 50% decrease in hepatic production of creatine; increases in the volume of distribution due to the accumulation of extracellular fluid, edema, and ascites; malnutrition and loss of muscle mass, which is related to repeated episodes of sepsis and large-volume ascites affecting satiety.2 Ultimately, patients with chronic liver disease have a significantly lower baseline serum creatinine concentration than the general population (35-75 μmol/l).

Patients with chronic liver disease display smaller and delayed (up to 48-72 hours) changes in serum creatinine for a given change in GFR, thus impairing the recognition and underestimating the degree of change in GFR.3,4 Detection of renal insufficiency is clinically important because it contributes significantly to high morbidity and mortality in cirrhosis. Moreover, renal dysfunction is one of the most important risk factors when liver transplantation is being considered. Patients with cirrhosis and renal failure are at high risk for death while awaiting transplantation and have an increased frequency of complications and reduced survival after transplantation, as compared with those without renal failure.

• Study Type: Observational
• Enrollment (Estimated): 150

Contacts and Locations

• Study Contact: Name: Reham Hossam Mohamed Ahmed; Phone Number: +201098190338; Email: reham_hossam_post@med.sohag.edu.eg
• Study Contact Backup: Name: Amal Khalifa Ahmed noureldin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

prevalence of renal dysfunction in chronic liver disease patients who admitted to sohag university hospital

Description

Inclusion Criteria:

- Data regarding demographic variables (age, weight, sex),

Evidence for chronic liver disease is defined by:

A compatible Clinical profile (signs of liver cell failure or reduced liver span) along with Biochemical (altered liver function tests, reversal of albumin globulin ratio, etc) or Sonographic evidence (altered echotexture of the liver) Diuretics will be withheld for 3 days before carrying out lab investigations.

Exclusion Criteria:

• • patients >70 years

  • Known primary renal disease or obstructive uropathy
  • Diabetes mellitus
  • Hypertension

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
prevalence of renal dysfunction in patients with chronic liver disease	prevalence of renal dysfunction in patients with chronic liver disease	during admission time at sohag university hospital

Collaborators and Investigators

• Sponsor: Sohag University

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2025
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): January 1, 2026

Study Registration Dates

• First Submitted: January 2, 2025
• First Submitted That Met QC Criteria: January 11, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 11, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Digestive System Diseases; Liver Diseases; Renal Insufficiency
• Other Study ID Numbers: Soh-Med--24-12-10MS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No